



**SZABO  
SCANDIC**

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](http://linkedin.com/company/szaboscandic)



# PRODUCT INFORMATION

**CP 105,696**

Item No. 17620

CAS Registry No.: 158081-99-3

Formal Name: 1-[(3S,4R)-3-([1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl]-cyclopentanecarboxylic acid

MF: C<sub>28</sub>H<sub>28</sub>O<sub>4</sub>


FW: 428.5

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

CP 105,696 is supplied as a solid. A stock solution may be made by dissolving the CP 105,696 in the solvent of choice, which should be purged with an inert gas. CP 105,696 is soluble in acetonitrile and DMSO.

## Description

CP 105,696 is an antagonist of the leukotriene B<sub>4</sub> (LTB<sub>4</sub>) receptor (IC<sub>50</sub> = 8.42 nM for the high-affinity receptor in human neutrophils).<sup>1</sup> It inhibits chemotaxis induced by LTB<sub>4</sub> (Item No. 20110) in isolated human neutrophils (IC<sub>50</sub> = 5 nM) and LTB<sub>4</sub>-induced calcium mobilization in isolated human monocytes (IC<sub>50</sub> = 940 nM). CP 105,696 reduces infiltration of neutrophils and eosinophils induced by arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) in guinea pig skin (ED<sub>50</sub> = 0.3 mg/kg, p.o.). It decreases blood glucose levels in the glucose tolerance test and reduces hepatic steatosis in a mouse model of obesity induced by a high-fat diet.<sup>2</sup> CP 105,696 decreases disease severity in a mouse model of experimental allergic encephalomyelitis (EAE; ED<sub>50</sub> = 8.6 mg/kg).<sup>3</sup> It increases graft survival in a mouse model of allogeneic heart transplantation when administered at a dose of 50 mg/kg.<sup>4</sup>

## References

1. Showell, H.J., Pettipher, E.R., Cheng, J.B., et al. The *in vitro* and *in vivo* pharmacologic activity of the potent and selective leukotriene B<sub>4</sub> receptor antagonist CP-105696. *J. Pharmacol. Exp. Ther.* **273**(1), 176-184 (1995).
2. Li, P., Oh, D.Y., Bandyopadhyay, G., et al. LTB<sub>4</sub> promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. *Nat. Med.* **21**(3), 239-247 (2015).
3. Gladue, R.P., Carroll, L.A., Milici, A.J., et al. Inhibition of leukotriene B<sub>4</sub>-receptor interaction suppresses eosinophil infiltration and disease pathology in a murine model of experimental allergic encephalomyelitis. *J. Exp. Med.* **183**(4), 1893-1898 (1996).
4. Weringer, E.J., Perry, B.D., Sawyer, P.S., et al. Antagonizing leukotriene B<sub>4</sub> receptors delays cardiac allograft rejection in mice. *Transplantation* **67**(6), 808-815 (2004).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.